News

  1. The Factor H family: four specific unmet challenges that need to be resolved

    This review was written in light of the perspective of principal investigators of the SciFiMed Consortium: a consortium aiming to create a comprehensive analytical system for the quantitative and functional assessment of the entire FH protein family. The FH-family consists of FH, FHL-1 and the five FHR proteins which are important regulators of the Read more...
  2. SciFiMed: Screening of inFlammation to enable personalized Medicine.

    We are proud to be part the international research project SciFiMed: Screening of inFlammation to enable personalized Medicine. With this international and interdisciplinary team we work on furthering immunological research and aim to enable new treatment methods and new approaches for the field of drug development. Prof. Pauly, entrusted with Read more...
  3. Increased window of detection: EHEC results now possible up to two months after infection!

    The EcHECk ELISA enables reliable detection of IgM antibodies against EHEC bacteria in serum up to two months after onset of infection. Detection of EHEC is currently performed by PCR or culturing and these methods are not able to identify EHEC after one week of infection. Using this ELISA kit to determine a possible EHEC infection will offer you a Read more...
  4. Complement and Thromboinflammation in SARS-CoV-2:

    When our adaptive immune system fails or responds too slow in pandemics, we need to be able to rely on our host defense and innate immune system. It has not only become more relevant for now, but also for future infections. As within the current SARS-CoV-2 / Covid-19 pandemic it is evident that the innate immune system has a pivotal role Read more...
  5. Hycult Biotech is partner in CORVOS: a unique European consortium focusing on complement

    Read more...
  6. Blocking the Terminal Complement pathway to preserve kidney function following renal IRI?

    Summary of Bongoni, A et al; Complement-mediated Damage to the Glycocalyx Plays a Role in Renal Ischemia-reperfusion Injury in Mice. Transplantation Direct 2019.   The impact of complement activation was investigated on glycocalyx integrity and renal dysfunction in a mouse model of renal IRI (Ischemia-Reperfusion Injury). Animals were tested Read more...
  7. Tools for Complement research in rodents

    Summary of Kotima, J et al; Functional assessment of rat complement pathway activities and quantification of soluble C5b-9 in an experimental model of renal ischemia/reperfusion injury. J Immunol Methods 2014. Complement activation is being monitored more in both clinical settings as experimental models. To support the research in rat, mouse (and Read more...
  8. Antibodies from 20UG to 100MG

    Antibodies up to 100 mg  Did you know that Hycult Biotech also offers bulk products? Several antibodies which are known to be interesting in larger quantities, are now available as standard catalog items. We have added them in 1, 5 and 10 mg bulk and we have added 50 and 100 mg for two of the best selling antibodies: TLR2, Mouse/Human, mAb Read more...
  9. Scaling up from µg to gram: CEO Hycult Biotech acquires Biocult

    Uden, The Netherlands, June 2019 – Mr. Ronald de Niet is pleased to announce the acquisition of Biocult. Biocult is an internationally operating company with 20 years’ experience in upscaling of monoclonal antibodies. Since Biocult was established in 1992, they have processed over 200 different cell lines including hybridomas, transfectomas. Read more...
  10. New biomarkers for NAFLD: PR3, NE and AAT

    Summary of Mirea, A et al; Increased proteinase 3 and neutrophil elastase plasma concentrations are associated with non-alcoholic fatty liver disease (NAFLD) and type 2 diabetes. Mol Med 2019.   Non-alcoholic fatty liver disease (NAFLD) is becoming a major health problem worldwide with a prevalence of approximately Read more...

Items 1-10 of 86

Page
Show per page